ALLR
Allarity Therapeutics Inc
$
1.020
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.030
Open
1.020
VWAP
1.00
Vol
310.87K
Mkt Cap
15.38M
Low
0.9894
Amount
311.26K
EV/EBITDA(TTM)
--
Total Shares
17.61M
EV
-8.46M
EV/OCF(TTM)
--
P/S(TTM)
--
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Show More
Valuation Metrics
The current forward P/E ratio for Allarity Therapeutics Inc (ALLR.O) is -0.02, compared to its 5-year average forward P/E of -0.79. For a more detailed relative valuation and DCF analysis to assess Allarity Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.79
Current PE
-0.02
Overvalued PE
0.28
Undervalued PE
-1.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.22
Undervalued EV/EBITDA
-0.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-28.40%
-3.04M
Operating Profit
FY2025Q1
YoY :
-28.91%
-2.73M
Net Income after Tax
FY2025Q1
YoY :
-99.96%
-0.25
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ALLR News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
08:05:43
Allarity announces new licensing, laboratory services agreement
2025-07-07 (ET)
2025-07-07
08:20:18
Allarity appoints Jeff Ervin as CFO
2025-06-30 (ET)
2025-06-30
08:13:38
Allarity gets Australian patent acceptance notice for DRP companion diagnostic
Sign Up For More Events
Sign Up For More Events
News
5.0
07-07NASDAQ.COMAllarity Therapeutics Appoints Jeff Ervin To Succeed Alexander Epshinsky As CFO
9.0
06-27NewsfilterAllarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
9.0
06-04NASDAQ.COMAllarity Teams With IBRI To Advance Dual-Action Cancer Drug Stenoparib
Sign Up For More News
People Also Watch
SNPX
TAO Synergies Inc
0
USD
+22.99%
NVFY
Nova LifeStyle Inc
2.290
USD
+13.37%
STKH
Steakholder Foods Ltd
1.045
USD
-4.13%
IMTE
Integrated Media Technology Ltd
1.150
USD
-8.73%
CTHR
Charles & Colvard Ltd
0
USD
-8.16%
SONN
Sonnet Biotherapeutics Holdings Inc
3.990
USD
-5.45%
XPON
Expion360 Inc
1.440
USD
+1.41%
ONCO
Onconetix Inc
4.150
USD
+14.96%
GLMD
Galmed Pharmaceuticals Ltd
1.990
USD
+0.51%
NCNA
NuCana PLC
0.060
USD
+11.11%
FAQ
What is Allarity Therapeutics Inc (ALLR) stock price today?
The current price of ALLR is 1.02 USD — it has increased 0 % in the last trading day.
What is Allarity Therapeutics Inc (ALLR)'s business?
What is the price predicton of ALLR Stock?
What is Allarity Therapeutics Inc (ALLR)'s revenue for the last quarter?
What is Allarity Therapeutics Inc (ALLR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Allarity Therapeutics Inc (ALLR)'s fundamentals?
How many employees does Allarity Therapeutics Inc (ALLR). have?